BNP Paribas Asset Management
EPRS

BNP Paribas Asset Management’s EPIRUS BIOPHARMACEUTICALS INC COM EPRS Stock Holding History

BNP Paribas Asset Management’s Portfolio EPRS Stock Details EPRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-19,395
Closed -$174K – 1120
2015
Q1 		$174K Buy
+19,395
New +$156K ﹤0.01% 1035

Other funds holding EPRS

Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
TGHSA
TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
B
Bailard Foster City, California $4.35B AUM 23.57% 1-Year Est. Return

BNP Paribas Asset Management's EPRS Position: Q2 2015 in Review

BNP Paribas Asset Management sold out of EPIRUS BIOPHARMACEUTICALS INC COM (EPRS) in Q2 2015, closing a stake of 19,395 shares — an estimated $174K sold.

BNP Paribas Asset Management first reported a position in EPRS in Q1 2015 and held it in 1 quarter. The position peaked at $174K in Q1 2015. 41 funds tracked by Wall St. Rank hold EPRS as of Q2 2015.

  • BNP Paribas Asset Management reported no remaining EPIRUS BIOPHARMACEUTICALS INC COM position as of Q2 2015 after selling out during the quarter.
  • BNP Paribas Asset Management sold 19,395 EPIRUS BIOPHARMACEUTICALS INC COM shares in Q2 2015, an estimated $174K.
  • BNP Paribas Asset Management first reported a position in EPIRUS BIOPHARMACEUTICALS INC COM in Q1 2015 and held it in 1 quarter.
  • BNP Paribas Asset Management's EPIRUS BIOPHARMACEUTICALS INC COM position peaked at $174K in Q1 2015.
  • 41 funds tracked by Wall St. Rank held EPIRUS BIOPHARMACEUTICALS INC COM as of Q2 2015.

Based on BNP Paribas Asset Management's 13F filing for Q2 2015, filed 14 Aug 2015.